Senescent “zombie” cells are linked to aging and multiple diseases, but spotting them in living tissue has been notoriously difficult. Researchers at Mayo Clinic have now taken an inventive leap by ...

Aptamer Group plc, a developer of synthetic oligonucleotide-based binding reagents for life sciences applications, and ...

Synthetic binders developer Aptamer Group has signed a licensing agreement with Alphazyme for the use of an Optimer binder in ...

Aptamer Group Plc ( (GB:APTA) ) has provided an update.

Binders will establish cell types and delivery vehicles may increase uptake of the siRNA therapy Binders will establish cell types and delivery vehicles may increase uptake of the siRNA therapy ...

The York-based Aptamer Group says it ends 2025 with strong momentum as global pharma partnerships drive confidence for 2026.

This schematic shows the secondary structure of two aptamers. The complex shapes formed by base pairing (black lines connecting G-C and A-T bases) allow aptamers to bind their targets with high ...

(RTTNews) - Aptamer Group (P0J.F, APTA.L) and Alphazyme, a Maravai LifeSciences (MRVI) company, have entered into a licensing agreement for a developed Optimer for use in hot-start PCR applications.

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Aptamer Group Plc ( (GB:APTA)) has ...

(Alliance News) - Aptamer Group PLC shares jumped on Friday as the firm said it has made progress across its enzyme modulation projects, including advancing its second inhibitor to the final ...